SCHEMBL3302932

SCHEMBL3302932

Cc1cc(-c2nc(N)c3cc(C(=O)N4CCOCC4)sc3n2)no1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.46
NPC1 O15118 9/20 0.46
SMN1; SMN2 Q16637 6/20 0.46
KDM4E B2RXH2 5/20 0.46
ALDH1A1 P00352 5/20 0.46
HPGD P15428 5/20 0.46
GAA P10253 3/20 0.46
TSHR P16473 3/20 0.46
HSD17B10 Q99714 2/20 0.46
GLA P06280 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
MAPT P10636 5/20 0.45
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
HTT P42858 2/20 0.45
ADORA2A P29274 3/20 0.43
ADORA1 P30542 2/20 0.43
TP53 P04637 4/20 0.43
USP2 O75604 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3301896 0.82 ADORA2A (0.64) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL3345101 0.82 HSP90AB1 (0.43) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL3296743 0.80 ADORA2A (0.64) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL3300639 0.78 ADORA2A (0.63) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL3301710 0.77 ADORA2A (0.64) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL3302010 0.77 ADORA2A (0.55) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL3302014 0.76 ADORA2A (0.67) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL13389395 0.74 ADORA2A (0.48) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL3302988 0.74 ADORA2A (0.47) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL3300716 0.74 ADORA2A (0.66) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010045008-A1 AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2010-04-22 WO disclosed
US-20100093714-A1 AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2010-04-15 US disclosed
US-20100093714-A1 AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2010-04-15 US disclosed
US-20100093714-A1 AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093714-A1 AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS ADORA2A, ADORA3, ADORA2B RAB9A 1239/4885NPC1 3954/4885SMN1; SMN2 840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.